

Haematologica
HAEMATOL/2019/243170
Version 3

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS

Vittorio Stefoni, Miriam Marangon, Alessandro Re, Arben Lleshi, Maurizio Bonfichi, Antonello Pinto, Nicola Bianchetti, Cinzia Pellegrini, Lisa Argnani, and Pier Luigi Zinzani

Disclosures: This study was partially supported by Takeda (ID X25008). All the Authors declare no conflicts of interest.

Contributions: P.L.Z., M.M., L.A. and V.S. conceived the study; P.L.Z., M.M., V.S. and L.A. designed the study, collected and, and wrote the manuscript; L.A. analyzed data; A.R., A.L., M.B., A.P., N.B., and C.P. provided advice and assisted with data collection and interpretation; all the authors approved the final manuscript.